|
|
|
|
| Join Drug Delivery Leader chief editor Tom von Gunden and a virtual panel of experts on February 4th at 11am ET for a discussion on innovations and advances in injectable, infusible, and implantable devices, systems, platforms, and combinations. Register for this free digital event thanks to sponsor BD Medical. |
|
|
|
|
By Tom von Gunden, chief editor, Drug Delivery Leader | In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape. | |
|
|
|
|
| De-Risking The Transition From Vial To Combination Product | Article | West Pharmaceutical Services, Inc. | When transitioning from a vial to a combination product system, the best approach is to have a holistic de-risk strategy with an intentional focus on the patient, the plan, and the product. |
|
|
|
| Container Selection For A Highly Sensitive Drug Product | Case Study | Stevanato Group | Learn about the importance of selecting the right container for sensitive drug products and how close collaboration is crucial for avoiding commercialization delays and safety risks to patients. |
|
|
|
|
|
.png){kind=logo}
